LEO Pharma Inc. Oct. 19 announced that the FDA has approved Enstilar for the topical treatment of plaque psoriasis in adults 18 years of age and older.
Enstilar (calcipotriene and betamethasone dipropionate) is a once-daily, alcohol-free foam formulation in a pressurized spray can that allows application across large body areas of plaque psoriasis. The company submitted the application for the product in January 13 PLIR 50, 1/9/15.
“The approval of Enstilar may offer the appropriate plaque psoriasis patients a new treatment option in an elegant vehicle that provides rapid relief from symptoms,” Barbara J. Osborne, president and chief executive ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.